| Author |
N |
Rx
(N) |
Symptomatic
Response |
Biochemical
Response,
CGA |
Disease Control
(CR / PR / SD) |
Median
TTP, mos |
Median
Survival, mos (range) |
Comments |
Cao
2010 |
58
(51 evaluable)
(42 carcinoid) |
SS |
NR |
NR |
58% (ITT) |
NR |
36
(1 – 61) |
1, 2, 3 yr OS:
86%/58%/47% |
| 10% |
24% |
24% |
Gulec
2007 |
10 |
SS |
NR |
NR |
100% |
NR |
NR |
|
| NR |
NR |
NR |
Kalinowski
2009 |
9 |
SS |
Increase QLQ-C30 & LMC21 at 3 mos & returns to baseline at 12 mos |
66% |
100% |
11.1 |
NR |
1, 2, 3 yr OS:
100%/57%/57%
Acute & late AEs: very low |
| 0% |
67% |
33% |
Kennedy+
2008 |
148 |
SS |
NR |
NR |
85.9% |
NR |
70 |
|
| 2.7% |
60.5% |
22.7% |
King*
2008 |
34 |
SS
+
5-FU |
3 mos: 55%
6 mos: 50% |
66% PR
Small bowel
60% PR
Pancreas |
50% |
NR |
29.4 |
1 early death from liver dysfunction |
| 18% |
32% |
|
Murthy
2008 |
8 |
SS |
NR |
NR |
62.5% |
NR |
14
(3-15) |
Radioembo safe with prior HA embolization |
| |
12.5% |
50% |
Rhee+
2008 |
42 |
SS (20)
TS (22) |
NR |
NR |
75% SS
55% TS |
NR |
28 SS
22 TS |
Compared resin (SS) vs glass (TS) |
| |
40% SS
32% TS |
35% SS
23% TS |
Saxena*
2010 |
48
(16 small bowel; 16 pancreas) |
SS |
NR |
NR |
78% |
NR |
35
(5 – 63) |
Significant inc in alkaline phosphatase over 6 mos |
| 15% |
40% |
23% |
*Updated report from the senior author +Overlap of institutions / authors